What Disqualifies You From Taking Tirzepatide? Contraindications & Who Shouldn't Take It (2026)

Only a short list of conditions truly disqualifies you from tirzepatide. Per the FDA prescribing information for Mounjaro and Zepbound on DailyMed, tirzepatide is contraindicated in just three situations: a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and a serious hypersensitivity reaction to tirzepatide or any of its ingredients.^[1][2] Those are the genuine "you cannot take this" items. Everything else you have read about — a history of pancreatitis, gallbladder disease, diabetic retinopathy, gastroparesis, type 1 diabetes, pregnancy, depression, or kidney problems — is a caution or a relative consideration that your prescriber weighs case by case, not an automatic disqualifier. This guide separates the absolute contraindications from the cautions, explains the BMI-based eligibility rules for weight management, flags the tirzepatide-specific oral birth control warning, and gives you a clear summary table. This is general educational information, not medical advice — your prescriber individualizes eligibility after reviewing your full history.

The short answer: who absolutely cannot take tirzepatide

The FDA label lists only three absolute contraindications for tirzepatide — the situations in which it should not be prescribed at all.^[1][2] Two of them are linked to the drug's boxed warning, the FDA's strongest safety alert, which is based on a finding in rodents that tirzepatide caused thyroid C-cell tumors (including medullary thyroid carcinoma). Whether this risk carries over to humans is not known, but the precaution is firm:

• Personal or family history of medullary thyroid carcinoma (MTC). If you or a close family member has had this specific, relatively rare thyroid cancer, tirzepatide is contraindicated. This is the human-relevant counterpart of the rodent C-cell tumor finding behind the boxed warning.^[1][2]
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). MEN 2 is an inherited condition that markedly raises the lifetime risk of medullary thyroid carcinoma, so it is an absolute contraindication for the same reason.^[1][2]
• Serious hypersensitivity to tirzepatide or any excipient. If you have had a serious allergic reaction — such as anaphylaxis or angioedema — to tirzepatide or to any inactive ingredient in the product, you must not take it again.^[1][2]

These three are the true disqualifiers. If none of them applies to you, you are not automatically ruled out — but several other conditions, covered next, can make you a poor candidate or call for extra caution and monitoring.

Cautions: conditions that may make you a poor candidate

Beyond the three contraindications, the §5 Warnings and Precautions section of the tirzepatide label flags a set of conditions that do not flatly disqualify you but require your prescriber to weigh the risk carefully, sometimes choose a different treatment, or monitor you closely.^[1][2] These are relative considerations — the decision is individualized.

• History of pancreatitis. Acute pancreatitis has been reported with tirzepatide. The drug was not studied in people with a prior history of pancreatitis, so a clinician may be more cautious, choose another option, or watch closely if you have had it before. See our guide on tirzepatide and pancreatitis.^[1][2]
• Severe gastrointestinal disease or gastroparesis. Tirzepatide slows stomach emptying. It has not been studied in people with severe gastrointestinal disease, including severe gastroparesis (a stomach-paralysis condition), so it is generally not recommended in those situations.^[1][2]
• Gallbladder disease. Acute gallbladder problems, including gallstones (cholelithiasis), have been reported with tirzepatide. A history of gallbladder disease is a reason for added caution and counseling, not an automatic bar.^[1][2]
• Type 1 diabetes. Tirzepatide is not indicated for type 1 diabetes and has not been studied as a treatment for it; it is intended for type 2 diabetes (Mounjaro) or chronic weight management (Zepbound).^[1]
• Diabetic retinopathy. In people with type 2 diabetes and a history of diabetic retinopathy, rapid improvement in blood sugar has been associated with a temporary worsening of retinopathy, so the label advises monitoring. This is mainly relevant to the diabetes (Mounjaro) population.^[1]
• Pregnancy, planning pregnancy, or breastfeeding. Tirzepatide is not recommended in pregnancy because animal data showed fetal harm, and weight loss offers no benefit during pregnancy. The Zepbound label says to discontinue it when pregnancy is recognized; unlike Wegovy, it does not set a stop window before a planned pregnancy. For breastfeeding, the label does not rule it out; it asks you and your clinician to weigh the benefits of breastfeeding against your need for the drug and any possible effect on the infant.^[2]
• Use of oral hormonal contraceptives (the pill). This is a tirzepatide-specific point. Because tirzepatide delays gastric emptying, the label warns that oral hormonal contraceptives may be less effective, especially when you start the drug and at each dose increase. The label advises switching to a non-oral contraceptive method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose escalation. See our guide on tirzepatide and birth control.^[1][2]
• History of suicidal thoughts or depression. The Zepbound label no longer says anything about this. The FDA removed the suicidal-behavior-and-ideation subsection in February 2026, after a pooled analysis of 91 placebo-controlled trials in 107,910 patients found no increased risk^[5]. A history of depression is still worth flagging at intake so your prescriber can watch mood through titration, and the FDA still asks patients to report new or worsening symptoms^[5].
• Severe kidney impairment. The gastrointestinal side effects (vomiting, diarrhea) can cause dehydration, which can in turn lead to acute kidney injury. People with kidney problems need extra caution and attention to hydration.^[1][2]

The honest framing is that almost everything on this list is a relative consideration, not a hard stop. A prescriber reviews your full medical history, your current medications, and your goals before deciding whether tirzepatide is appropriate for you. If you want a side-by-side of the two leading GLP-1 medications, see our tirzepatide vs semaglutide comparison, and our companion guide on what disqualifies you from semaglutide covers the closely related contraindication list for that drug.

Summary table: absolute vs caution

Eligibility: who qualifies for tirzepatide for weight management

Not being disqualified is only half the question. To be a candidate for Zepbound (tirzepatide for chronic weight management), you also have to fit the §1 Indications and Usage section of the label, which covers adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition, alongside a reduced-calorie diet and increased physical activity.^[2] The label itself prints no BMI numbers. In practice, prescribers apply the CDC's adult definition of obesity and the entry criteria of the SURMOUNT-1 trial that supported the approval, which means adults who have:^[6][3]

• A body mass index (BMI) of 30 or higher (obesity), or
• A BMI of 27 or higher (overweight) together with at least one weight-related health condition — for example high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).

Zepbound also carries a separate FDA indication to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, used alongside a reduced-calorie diet and increased physical activity — so for some patients the qualifying condition is OSA plus obesity rather than BMI alone.^[2] In the pivotal SURMOUNT-1 trial that supported the weight-management approval, adults taking tirzepatide lost roughly 15% to 21% of body weight on average over 72 weeks across the 5 mg to 15 mg doses, versus about 3% on placebo — the magnitude benchmark that defines what the drug does at its labeled doses.^[3]

Eligibility for the diabetes version of tirzepatide differs. Mounjaro is indicated to improve blood sugar in adults with type 2 diabetes, so the qualifying condition there is the diabetes diagnosis, not a BMI threshold.^[1] If your goal is weight loss specifically, the BMI criteria above are the relevant test. The bottom line: you qualify if you meet the BMI rule (or the OSA-plus-obesity indication), you have no absolute contraindication, and your prescriber judges the cautions above to be manageable in your case.

Most disqualifiers are relative — a clinician decides

The most important takeaway is that the genuine, no-exceptions disqualifiers are short: medullary thyroid carcinoma history, MEN 2, and serious hypersensitivity. Almost every other concern you have seen described as a "disqualifier" — pancreatitis, gallbladder disease, kidney problems, depression, gastrointestinal conditions — is a relative caution that a prescriber individualizes after reviewing your history, your other medications, and your goals.^[1][2] Some of those cautions will lead a clinician to choose a different medication; others are managed with monitoring and careful titration.

This article is general education, not a substitute for that personalized review. The way to get a real answer for your situation is a proper medical evaluation. If you want to start that process under proper supervision, compare the best tirzepatide providers — legitimate providers screen you for the contraindications and cautions above before prescribing, which is exactly the safeguard that makes treatment appropriate. Your prescriber, not a checklist, makes the final eligibility decision. New to GLP-1s? Start with who qualifies for GLP-1 weight-loss medication.